Literature DB >> 8564140

Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS.

M Lutfey1, P Della-Latta, V Kapur, L A Palumbo, D Gurner, G Stotzky, K Brudney, J Dobkin, A Moss, J M Musser, B N Kreiswirth.   

Abstract

Historically, infections caused by Mycobacterium tuberculosis have been treated simultaneously with isoniazid and rifampin. As a consequence of this combined therapy, strains resistant only to rifampin were rarely recovered. However, recently there has been an increasing number of reports describing HIV-positive patients infected with mono-rifampin-resistant M. tuberculosis strains. Organisms cultured from seven patients (including six with AIDS) with infections caused by mono-rifampin-resistant M. tuberculosis, and seen at one New York City hospital, were analyzed by molecular techniques to test the hypothesis that dissemination of a single clone had occurred. IS6110 DNA fingerprinting and automated DNA sequencing of a region of the RNA polymerase beta subunit structural gene (rpoB) containing mutations that confer rifampin resistance showed that all organisms independently acquired the mono-rifampin-resistant phenotype. Molecular analysis of mono-rifampin-resistant organisms cultured from 13 additional patients in New York City confirmed independent strain origin. The data rule out the possibility of person-to-person strain transmission among these patients, and they suggest that host factors such as poor compliance with antituberculosis medications or decreased absorption of rifampin have been a driving force in the origin of these strains.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8564140     DOI: 10.1164/ajrccm.153.2.8564140

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  21 in total

1.  Multidrug-Resistant Tuberculosis in Patients with Human Immunodeficiency Virus. Management Considerations within High-resourced Settings.

Authors:  John W Wilson; Diana M Nilsen; Suzanne M Marks
Journal:  Ann Am Thorac Soc       Date:  2020-01

2.  Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.

Authors:  S L Moghazeh; X Pan; T Arain; C K Stover; J M Musser; B N Kreiswirth
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

Review 3.  Molecular epidemiology of tuberculosis: current insights.

Authors:  Barun Mathema; Natalia E Kurepina; Pablo J Bifani; Barry N Kreiswirth
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

4.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

5.  Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa.

Authors:  F K Mukinda; D Theron; G D van der Spuy; K R Jacobson; M Roscher; E M Streicher; A Musekiwa; G J Coetzee; T C Victor; B J Marais; J B Nachega; R M Warren; H S Schaaf
Journal:  Int J Tuberc Lung Dis       Date:  2012-02       Impact factor: 2.373

6.  Cross-matching TB and AIDS registries: TB patients with HIV co-infection, United States, 1993-1994.

Authors:  M Moore; E McCray; I M Onorato
Journal:  Public Health Rep       Date:  1999 May-Jun       Impact factor: 2.792

7.  Global Impact of Multidrug-Resistant Pulmonary Tuberculosis Among HIV-Infected and Other Immunocompromised Hosts: Epidemiology, Diagnosis, and Strategies for Management.

Authors:  Charles D Wells
Journal:  Curr Infect Dis Rep       Date:  2010-05       Impact factor: 3.725

8.  Antituberculosis drug resistance acquired during treatment: an analysis of cases reported in California, 1994-2006.

Authors:  Travis C Porco; Peter Oh; Jennifer M Flood
Journal:  Clin Infect Dis       Date:  2012-12-07       Impact factor: 9.079

Review 9.  Tuberculosis and HIV disease: two decades of a dual epidemic.

Authors:  Muktar H Aliyu; Hamisu M Salihu
Journal:  Wien Klin Wochenschr       Date:  2003-10-31       Impact factor: 1.704

Review 10.  Extensively drug-resistant tuberculosis: a new face to an old pathogen.

Authors:  Sheela Shenoi; Gerald Friedland
Journal:  Annu Rev Med       Date:  2009       Impact factor: 13.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.